Kharkov National Medical University, Ukraine
Multiple sclerosis (MS)
is a serious neurological problem because of its high prevalence, chronic
course, frequent disability, and propensity to affect young people. The immunopathogenesis hypothesis
underlies the origin of MS. Selective sorption activity of biocompatible
magnetite nanoparticles against surface proteins of cell membranes, circulating
immune complexes, lymphocytotoxic antibodies, complement system, the effect of
increasing phagocytic activity and leukocyte phagocytosis completion index
allows the effective use of these nanodevices for immunocorrection. The main
goal of the study is to slow down the progression of MS, improve the
neurological status and general condition of the patient, and reduce the
dynamics of the spread of demyelinating foci in the brain. Materials and
methods: a patient diagnosed with multiple sclerosis, secondary progressive
type of course, cerebro-spinal form, clinical aggravation stage; EDSS
neurological status and disability assessment scales; contrast-enhanced MRI of
the brain. An oral form of the nanodevice Micromage-B was used as an
immunosorbent and immunomodulator. The choice of the regimen and dosage of
Micromage-B was personalized. Assessment of the general condition and
neurological status was performed every 7 days for 6 months. Contrast-enhanced
MRI of the brain was performed at the 5th month of the study. As a result of using
Micromage-B in MS treatment, objective improvement of neurological status,
reduction of stiffness and rapid fatigability of the lower extremities were
observed. Gait and coordination improved, hand tremors decreased, depression
and signs of concentration disorders disappeared, appetite restored, and speech
improved. During the entire period of Micromage-B application, positive
dynamics in the normalization of the neurological status was observed. After 6
months of treatment, the total score dropped by 210 to 45. It was found that
the maximum positive effect was observed in the evaluation of the pyramidal
system and coordination. The EDSS Disability Scale score decreased from 6.0 to
5.0. Contrast-enhanced MRI brain examination for the first time showed a
decrease in the number of new foci of demyelination in the brain by the 4th
month of Micromage-B administration. The positive dynamics of normalization of
the neurological status correlated with the results of brain MRI. The process
of recovery of central nervous system activity in MS is not only due to the
immunosuppressive properties of magnetite nanoparticles, but is probably caused
by the activation of remyelination mechanisms and oligodendrocyte
differentiation through enzymatic methylation. Considering the above, the use
of biocompatible nanodevices in the complex treatment of MS is a promising
direction. The scheme and method of using biocompatible magnetite nanoparticles
to improve the effectiveness of MS treatment require further improvement and study.
Andrey Nikolaevych
Belousov is Doctor of Medicine degree on speciality - Anesthesiology and
Intensive Care. Author a new medicine products – nanotechnology preparations
based on magnetite nanoparticles (Fe3O4)
(www.nanolab.com.ua): Micromage-B (officially registration in Ukraine);
Magnet-controlled sorbent brand of MCS-B for extracorporeal detoxication of
biological liquids (officially registration in Ukraine and was allowed for
medical practice); NanoBiocorrector for intravenous application – ICNB
(intracorporal nanosorbent). A.N. Belousov is author new method of
extracorporeal hemocorrection using magnet-controlled sorbent (MCS-B). The
published more 280 scientific works on results application of nanotechnology
preparation in experimental and practical medicine. At now Andrey Belousov -
the Head of Laboratory Applied Nanotechnologies in Ukraine, DM, Professor of
Kharkiv National Medical University, Ukraine.